In this episode, host Melissa Kramer speaks with Amanda Burkardt and Dr. Mayukh Das from Phiogen, a biotechnology company developing bacteriophage (phage) therapeutics for recurrent urinary tract infections (UTIs). They describe how their novel approach utilizes targeted viruses to eliminate UTI-causing bacteria, without harming the microbiome. You’ll hear how Phiogen’s science tackles the most challenging cases, including chronic and antibiotic-resistant UTIs, and why they’re inviting patients to help shape the future clinical trial that Phiogen will be running.

If you’ve ever wondered whether phage therapy could be a solution for your chronic UTI, especially if you’ve struggled with negative cultures, biofilms, or treatment resistance, this episode is for you.

🎧 What You’ll Learn in This Episode:

• How phage therapy works, and why it’s different from antibiotics
  
  
  
• Why recurrent UTI patients, especially those with antibiotic resistance or biofilms, may benefit most from phage therapy
  
  
  
• What’s happening behind the scenes to bring an “off-the-shelf” phage treatment to clinical trials
  
  
  
• The current limitations (e.g., E. coli-only focus) and plans for expanding phage therapy access
  
  
  
• How YOU can shape the upcoming clinical trial by joining the patient survey

Want to learn more about urinary health? Visit LiveUTIFree.com for expert articles on the latest research, or check out our YouTube channel for a video format.